Literature DB >> 4215726

Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement.

W Vogt, L Dieminger, R Lynen, G Schmidt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4215726     DOI: 10.1515/bchm2.1974.355.1.171

Source DB:  PubMed          Journal:  Hoppe Seylers Z Physiol Chem        ISSN: 0018-4888


× No keyword cloud information.
  14 in total

1.  Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea-pig peritoneal macrophages in vitro.

Authors:  C Bentley; W Fries; V Brade
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

2.  Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex.

Authors:  Bert J C Janssen; Lucio Gomes; Roman I Koning; Dmitri I Svergun; Abraham J Koster; David C Fritzinger; Carl-Wilhelm Vogel; Piet Gros
Journal:  EMBO J       Date:  2009-07-02       Impact factor: 11.598

3.  Complement bridges between cells analysis of a possible cell-cell interaction mechanism.

Authors:  M P Dierich; B Landen
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

4.  Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Authors:  H W Virgin; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

5.  The activation of the C3b feedback cycle with human complement components. I. Through the classical pathway.

Authors:  L W Mak; P J Lachmann; J Majewski
Journal:  Clin Exp Immunol       Date:  1977-11       Impact factor: 4.330

6.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

Authors:  J B Ziegler; C A Alper; R S Rosen; P J Lachmann; L Sherington
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

7.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

8.  Incompatibility between C3b and B of guinea-pig and man and its influence on the titration of the alternative pathway factors D and B in these two species.

Authors:  V Brade; L Dieminger; G Schmidt; W Vogt
Journal:  Immunology       Date:  1976-02       Impact factor: 7.397

9.  New synthetic inhibitor to the alternative complement pathway.

Authors:  N Ikari; Y Sakai; Y Hitomi; S Fujii
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

10.  A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.

Authors:  F B Waldo; J Forristal; L Beischel; C D West
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.